Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
An interventional study of digital therapy on blood glucose and weight management in Chinese patients with type 2 diabetes.
J Diabetes Investig
January 2025
Department of Endocrinology, Peking University First Hospital, Beijing, China.
Objective: Our study aimed to evaluate the effectiveness of a 3-months digital therapy (DTx) intervention in the real world for the management of blood glucose in 3,902 Chinese patients with type 2 diabetes (T2D) in Lingshui, Hainan.
Methods: Adults with T2D who were capable of using DTx application (app) were enrolled. Fasting blood glucose (FBG), 2-h postprandial blood glucose (2hPBG), and body weight before and after the intervention were collected.
The effects of intermittent fasting on antioxidant and inflammatory markers and liver enzymes in postmenopausal, overweight and obese women with rheumatoid arthritis: a randomized controlled trial.
Sci Rep
January 2025
Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, P.O. Box 14155-6117, Tehran, Iran.
Rheumatoid arthritis (RA) is a chronic inflammatory disorder affecting postmenopausal women. This study investigated the effects of intermittent fasting (IF) on antioxidant and inflammatory markers and liver enzymes in postmenopausal, overweight and obese women with RA. This 8-week randomized controlled trial included 44 postmenopausal women with RA divided into an intervention group following a 16:8 IF diet and a control group maintaining their usual diet and received recommendations for healthy eating.
View Article and Find Full Text PDFPan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD.
J Hepatol
January 2025
Division of Endocrinology, Diabetes and Metabolism, University of Florida, Gainesville, Florida, United States of America. Electronic address:
Background & Aims: Lanifibranor is a pan-PPAR agonist that improves glucose/lipid metabolism and reverses steatohepatitis and fibrosis in adults with MASH. We tested its effect on insulin resistance at the level of different target tissues in relationship to change in intrahepatic triglyceride (IHTG) content.
Methods: This phase 2, single center, study randomized (1:1) 38 patients with T2D and MASLD to receive lanifibranor 800 mg or placebo for 24 weeks.
Evaluating the Antidiabetic Activity of Latex in Alloxan-Induced Diabetic Rats and the Development of a Novel Effervescent Granule-Based Delivery System.
ScientificWorldJournal
January 2025
Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Sana'a University, Sana'a, Yemen.
Ethnomedicine exhibits potential in developing affordable effective antidiabetic agents. This work aimed to explore the antidiabetic properties of latex extract both in vivo, utilizing alloxan-induced diabetic rats, and in vitro, through -amylase enzyme testing. Additionally, it sought to formulate optimal effervescent granules derived from the extract.
View Article and Find Full Text PDFUnlocking prognostic potential: A genomic signature of caloric restriction in patients with epithelial ovarian cancer.
PLoS One
January 2025
Faculty of Natural Sciences, Department of Molecular Biology, Ariel University, Ariel, Israel.
Objectives: Epithelial ovarian cancer is a significant contributor to cancer-related mortality in women, frequently recurring post-treatment, often accompanied by chemotherapy resistance. Dietary interventions have demonstrated influence on cancer progression; for instance, caloric restriction has exhibited tumor growth reduction and enhanced survival in animal cancer models. In this study, we calculated a transcriptomic signature based on caloric-restriction for ovarian cancer patients and explored its correlation with ovarian cancer progression.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!